Treatment of non-insulin-dependent diabetes mellitus

被引:9
作者
Patel, M [1 ]
Rybczynski, PJ [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA
关键词
adult onset; DPP-IV; GSK3; hyperglycaemia; insulin sensitiser; NIDDM; PPAR; RXR; SGLT; type II diabetes mellitus;
D O I
10.1517/13543784.12.4.623
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes mellitus has been declared to be at an epidemic level by the World Health Organization. The syndrome is characterised as either Type I (insulin-dependent) or Type II (non-insulin-dependent) diabetes mellitus. Impaired glucose tolerance for extended periods of time results in serious complications such as kidney damage and impaired blood circulation and is the main cause for blindness and amputations in patients with diabetes. A combination of life-style change, dietary change and oral medications can treat Type II diabetes mellitus effectively and prevent long-term complications. Combination therapy appears to be the most effective approach in controlling blood glucose levels. This review updates the progress made in medicinal chemistry towards promising biological targets, with the development of a new generation of small molecules having improved efficacy and safety profiles.
引用
收藏
页码:623 / 633
页数:11
相关论文
共 66 条
[1]  
AHRN B, 2001, DIABETES S1, V50, P416
[2]   Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B [J].
Andersen, HS ;
Olsen, OH ;
Iversen, LF ;
Sorensen, ALP ;
Mortensen, SB ;
Christensen, MS ;
Branner, S ;
Hansen, TK ;
Lau, JF ;
Jeppesen, L ;
Moran, EJ ;
Su, J ;
Bakir, F ;
Judge, L ;
Shahbaz, M ;
Collins, T ;
Vo, T ;
Newman, MJ ;
Ripka, WC ;
Moller, NPH .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) :4443-4459
[3]  
[Anonymous], [No title captured]
[4]   Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401 - Inhibition and inactivation of glycogen phosphorylase by an activated metabolite [J].
Bergans, N ;
Stalmans, W ;
Goldmann, S ;
Vanstapel, F .
DIABETES, 2000, 49 (09) :1419-1426
[5]  
BERGMAN JP, 2001, 221 AM CHEM SOC NAT
[6]  
Blaskovich MA, 2002, EXPERT OPIN THER PAT, V12, P871
[7]  
BOUERES JK, 2001, 221 AM CHEM SOC NAT
[8]  
BOWLER AN, 2000, 16 INT S MED CHEM BO
[9]   Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids:: A new class of dual PPARα/γ agonists [J].
Brooks, DA ;
Etgen, GJ ;
Rito, CJ ;
Shuker, AJ ;
Dominianni, SJ ;
Warshawsky, AM ;
Ardecky, R ;
Paterniti, JR ;
Tyhonas, J ;
Karanewsky, DS ;
Kauffman, RF ;
Broderick, CL ;
Oldham, BA ;
Montrose-Rafizadeh, C ;
Winneroski, LL ;
Faul, MM ;
McCarthy, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (13) :2061-2064
[10]  
CHEN X, 2001, DIABETES S2, V50, P2153